Zealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertide
Royalty Pharma (RPRX) agreed to purchase Zealand Pharma’s economic interests in rusfertide for $100 million, securing a 1% royalty on global net sales and regulatory milestones. The transaction structure includes a $50 million upfront payment and a $50 million payment due one year post-closing, with Royalty Pharma retaining a 0.75% royalty on sales exceeding $1.5 billion.
Key figures
- Deal Value Usd
- 100000000
- Drug name
- rusfertide (PTG-300)
- Upfront payment usd
- 50000000
- Deferred payment usd
- 50000000
- Royalty rate percent
- 1
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.